Assessing patients' understanding of hepatitis C virus infection and its impact on their lifestyle

Department of Infectious Diseases and Tropical Medicine, S. Bortolo Hospital, Vicenza, Italy.
Alimentary Pharmacology & Therapeutics (Impact Factor: 5.73). 05/2006; 23(8):1161-70. DOI: 10.1111/j.1365-2036.2006.02882.x
Source: PubMed


To assess how much patients with hepatitis C virus infection know about their condition and what impact it has on their lifestyle.
A multiple-choice questionnaire was administered anonymously to 364 hepatitis C virus-infected subjects just before their first specialist visit.
Even before hepatitis C virus infection was diagnosed, 257 subjects (70.6%) already knew something about this infection. Overall, 36% of patients had changed the way they behaved within the family, 25.5% had changed their sexual habits, 46.9% had changed their diet, and 69% reported having stopped or limited their alcohol intake after being told they were hepatitis C virus positive. Hepatitis C virus infection had a negative impact on the psychological status in 44.2% of patients. This effect was significantly greater among women and was independent of either the duration of their infection or any counselling received from the general practitioner. The need for specific treatment was reported by 59.8%. A demand for more detailed information about hepatitis C virus was expressed by 89.9% of patients.
Hepatitis C virus changes all aspects of lifestyle and psychological status. The patients' strong demand for more information suggests that counselling and educational programmes must be an integral part of the activities of both the general practitioner and the specialist.

Download full-text


Available from: Maria Teresa Giordani, Sep 06, 2014
  • Source
    • "However, even after diagnosis with HCV, high-risk behaviors continue (Hagan et al., 2006; Ompad, Fuller, Vlahov, Thomas, & Strathdee, 2002). The initial diagnosis of HCV had a strong, negative emotional effect in almost half of a patient group that was not primarily composed of intravenous drug users (Fabris et al., 2006). For intravenous drug users, an HCV diagnosis is sometimes thought to be less momentous than for nonintravenous drug users, but that may not always be true (Treloar & Rhodes, 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The objective of this study was to assess craving and mood related to opioid and cocaine use among asymptomatic hepatitis C virus (HCV)+ and HCV- methadone patients who have not started antiviral treatment. Methods: In this 28-week prospective ecological momentary assessment (EMA) study, 114 methadone-maintained, heroin- and cocaine-abusing individuals reported from the field in real time on their mood, craving, exposure to drug-use triggers, and drug use via handheld computers. Results: Sixty-one percent were HCV+; none were overtly symptomatic or receiving HCV treatment. HCV status was not associated with age, sex, race, or past-30-day or lifetime heroin or cocaine use. In event-contingent EMA entries, HCV+ individuals more often attributed use to having been bored, worried, or sad; feeling uncomfortable; or others being critical of them compared with HCV- participants. In randomly prompted EMA entries, HCV+ participants reported significantly more exposure to drug-use triggers, including handling ≥$10, seeing cocaine or heroin, seeing someone being offered/use cocaine or heroin, being tempted to use cocaine, and wanting to see what would happen if they used just a little cocaine or heroin. Conclusions: HCV+ individuals experienced more negative moods and more often cited these negative moods as causes for drug use. HCV+ individuals reported greater exposure to environmental drug-use triggers, but they did not more frequently cite these as causes for drug use. The EMA data reported here suggest that HCV+ intravenous drug users may experience more labile mood and more reactivity to mood than HCV- intravenous drug users. The reason for the difference is not clear, but HCV status may be relevant to tailoring of treatment.
    Health Psychology 07/2014; 33(7):710-719. DOI:10.1037/hea0000087 · 3.59 Impact Factor
  • Source
    • "As evidências empíricas têm, todavia, apontado, de forma mais consistente, o lado negativo das doenças crônicas que, conforme citado, incluem a associação de sintomas de ansiedade, depressão, prejuízos na qualidade de vida e raiva/hostilidade associados à medicação utilizada para o tratamento (Amodio e cols., 2005; Kraus, Schäfer, Faller, Csef, & Scheurlen, 2003). A natureza dos conflitos psicológicos vivenciados pelos portadores de hepatite C segue, todavia, insuficientemente compreendida, havendo ainda grande carência de estudos sobre o impacto da doença nos relacionamentos familiares e com o parceiro amoroso (Blasiole e cols., 2006; Fabris e cols., 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: People suffering from chronic hepatitis C have great probability of presenting psychopathologic symptoms and difficulties on relationships with romantic partners. This study aimed to estimate the internal consistency, convergent validity and discriminant validity of the Central Relationship Questionnaire 6.0 (CRQ 6.0) for adults with chronic hepatitis C. The CRQ 6.0 is a self-report, developed to assesses the individuals relationship patterns according to three components: Wishes (W), Responses from Others (RO), Responses of Self (RS). Participants were patients with chronic hepatitis C (G1, n = 61) and persons who accompanied patients (G2, n = 40). They answered to the CRQ 6.0 and to the Symptoms Assessment Scale-40 (EAS-40). Results pointed to the acceptable internal consistency of the CRQ 6.0s components. They significantly correlated to psychopathological symptoms with EAS-40. Scores of the CRQ 6.0 were significantly higher for: participants of G1 (RO, RS), participants under medication (RS) and women (W, RS).
    Paidéia (Ribeirão Preto) 08/2010; 20(46):219-227. DOI:10.1590/S0103-863X2010000200009

  • World Journal of Gastroenterology 01/2007; 13(19):2722. DOI:10.3748/wjg.v13.i19.2722 · 2.37 Impact Factor
Show more